The BRIDGE HCV initiative encourages medical specialists, primary care clinicians, and substance use disorders (SUD)–services providers to actively expand treatment of chronic hepatitis C virus (HCV) infection to include individuals with recent or ongoing injection drug use. This can lead to substantial reductions in HCV prevalence and transmission, benefiting both the individual and the community. These benefits are especially effective when combined with harm-reduction interventions. Strong local HCV-care networks with structured collaboration further help build bridges to HCV-infected people who inject drugs (PWID) and allow these at-risk individuals access to highly effective direct-acting antiviral therapies. This 2-part educational series offers cutting-edge strategies for collaboratively reaching and treating HCV-positive PWID. Presenting the critical balance between clinical data and real-world experience and insights, these activities will give participants the opportunity to listen to nationally recognized HCV experts as they discuss these topics and offer hands-on tactics and practical resources to use in the clinical setting.

modules
Webcast 
0.75 CME

HCV in People Who Inject Drugs

Webcast 
0.75 CME

Addressing the Real-World Challenge of HCV Cure in People Who Inject Drugs

available resources
interactive presentation
linked resources
Suggested Reading
Meeting Series

BRIDGE HCV

Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV